Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib:A case report  

作　　者：Jia-Ping Qi Huan Jiang Teng Wu Yuan Zhang Wei Huang Yi-Xuan Li Jing Wang Ju Zhang Zhen-Hua Ying 

机构地区：[1]Graduate School,Bengbu Medical College,Bengbu 233030,Anhui Province,China [2]Center for General Practice Medicine,Department of Rheumatology and Immunology,Zhejiang Provincial People's Hospital,Affiliated People's Hospital,Hangzhou 310000,Zhejiang Province,China [3]Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine Cultivation for Arthritis Diagnosis and Treatment,Zhejiang Provincial People's Hospital,Affiliated People's Hospital,Hangzhou Medical College,Hangzhou 310000,Zhejiang Province,China [4]The Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310000,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2023年第11期2474-2481,共8页世界临床病例杂志

摘　　要：BACKGROUND Sporadic cases of rheumatoid arthritis(RA)due to unsatisfactory responses to Abatacept(ABT)have been reported;however,the rescue therapy has not been finalized.Here,we present a case with difficult-to-treat RA(D2T RA)that was resistant to either a single ABT or a Janus kinase(JAK)inhibitor(Tofacitinib),but improved with a combination of ABT and JAK inhibitor(Baricitinib,BAT).CASE SUMMARY A 46-year-old Chinese woman who had RA for ten years that was resistant to Tocilizumab,Etanercept,Adalimumab,and ABT.According to the European League Against Rheumatism definition,the patient was diagnosed with D2T RA.It was then improved with a combination of ABT and a JAK inhibitor BAT.CONCLUSION ABT combined with BAT may be an acceptable strategy for treating D2T RA.

关 键 词：Difficult-to-treat rheumatoid arthritis ABATACEPT Baricitinib Combination therapy Case report 

分 类 号：R593.22[医药卫生—内科学]